Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bottle and glass: Cephalon recalls Treanda after glass fragments found in vial

This article was originally published in Scrip

Executive Summary

Teva's Cephalon has voluntarily recalled one lot of its injectable leukaemia drug Treanda (bendamustine HCL), after glass fragments were found in one of the vials. The affected lot was distributed between March and October 2011, and Teva does not believe that much of the lot remains in stock. The FDA has warned that potential safety issues include disruption of blood flow resulting in tissue/organ damage, though Cephalon has so far received no reports of adverse events. Patients have been advised to return the product and cease using it, and wholesalers, distributors, hospitals and providers have been notified.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts